A PHASE 1, RANDOMIZED, OPEN-LABEL STUDY IN HEALTHY PARTICIPANTS TO ESTIMATE THE BIOAVAILABILITY OF TWO NEW ENCORAFENIB FORMULATIONS RELATIVE TO THE CURRENT FORMULATION AND TO EVALUATE THE EFFECT OF A PROTON-PUMP INHIBITOR ON ENCORAFENIB PLASMA PHARMACOKINETICS
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Encorafenib (Primary) ; Rabeprazole (Primary)
- Indications Brain metastases; Colorectal cancer; Glioma; Haematological malignancies; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Acronyms ERBA
- Sponsors Pfizer
Most Recent Events
- 02 Nov 2022 Status changed from recruiting to completed.
- 03 Aug 2022 Status changed from not yet recruiting to recruiting.
- 12 Jul 2022 New trial record